The performance of GAAD (Cobas), GALAD (Cobas), and GALAD (μTASWAKO) was superior to individual biomarkers (AFP, AFP-L3, and PIVKA-II) alone across HCC stages (Fig. 5A–D). This evidence concerns the gene AFP and hepatocellular carcinoma.